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Background: This study compared the beliefs held by individuals with coexisting serious 
mental illness and type 2 diabetes regarding the necessity and risks of taking antipsychotic 
versus hypoglycemic medications. We also investigated whether nonadherent patients differed 
from adherent patients in their beliefs about medications.
Methods: Forty-four individuals with type 2 diabetes and serious mental illness who were 
prescribed hypoglycemic and antipsychotic medications completed a cross-sectional assessment 
of medication beliefs and adherence for both medication types.
Results: Patients perceived a greater need for hypoglycemic versus antipsychotic medications; 
however, their beliefs were not associated with nonadherence to either medication type.
Conclusion: These results suggest that individuals with coexisting serious mental illness and 
type 2 diabetes have stronger convictions regarding the necessity of their diabetes medication 
for maintaining their health.
Keywords: nonadherence, antipsychotic medication, type 2 diabetes, medication beliefs, 
hypoglycemic medication, serious mental illness
Introduction
Nonadherence to antipsychotic medications is common in individuals with   schizophrenia 
and other serious mental illness, with an estimated 50% of individuals characterized as 
nonadherent.1 Nonadherence to antipsychotic medication has been linked with symptom 
relapse, worse prognosis, increased hospital use, and high health care costs.2–5
Patient attitudes towards antipsychotic medications are an important contributing 
factor in the decision to adhere to an antipsychotic medication regimen.6   Negative 
attitudes towards antipsychotic medication (eg, believing that one’s body and mind 
are “controlled” by medication, or that one is “doped up” when adhering to antipsy-
chotic prescriptions) are consistently related to nonadherence, both in cross-sectional7 
and longitudinal8 studies. Using the Beliefs about Medication Questionnaire,9 
  Jónsdóttir et al10 found that patients with serious mental illness who were nonadher-
ent to   psychotropic medication of any type felt medication to be less necessary and 
expressed greater concerns about medications than adherent patients. Similarly, 
greater concern about the risks of antipsychotic use (measured with the Beliefs about 
Medication   Questionnaire) was associated with greater nonadherence in a sample of 
individuals with schizophrenia or schizoaffective disorder who were prescribed either 
depot or oral antipsychotic medication.11
Individuals with serious mental illness are particularly susceptible to the develop-
ment of chronic medical conditions, such as type 2 diabetes.12,13 Because medication 
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is critical for the management of such conditions, a more 
in-depth understanding of beliefs about medications for 
chronic medical conditions and adherence in individuals with 
serious mental illness is needed. Medication attitudes have 
predicted adherence for individuals with chronic medical 
conditions and no history of mental illness. In a “chronic ill-
ness” sample, some of whom were diagnosed with diabetes, 
stronger beliefs about the necessity of medication for main-
taining health were associated with better medication adher-
ence, and greater concerns about the adverse consequences 
of medication were associated with poorer adherence.9
Recent research has demonstrated that the hypoglycemic 
medication adherence of individuals with coexisting serious 
mental illness and diabetes is better than that of diabetes 
patients with no history of mental illness,14,15 and that these two 
patient groups share similar attitudes regarding the necessity 
and risks of hypoglycemic medication.15 Despite the preva-
lence of coexisting medical conditions among persons with 
serious mental illness and the high rates of premature mortal-
ity in this population, no previous studies have   compared the 
beliefs of individuals with serious mental illness regarding 
their medications for medical conditions, such as diabetes, 
to their beliefs about antipsychotic medications.
An understanding of differential medication beliefs and 
adherence can inform interventions to promote adherence and 
help individuals to self-manage multiple complex chronic 
conditions more effectively. To this end, within a well char-
acterized cohort of patients with serious mental illness and 
type 2 diabetes, this study compared patients’ beliefs about 
hypoglycemic medications with their beliefs about antip-
sychotic medications, evaluated the relationship between 
beliefs and nonadherence for both types of medication, and 
compared nonadherence with antipsychotic versus hypogly-
cemic medications. We hypothesized that beliefs about the 
necessity and risk of hypoglycemic medication use would be 
associated with nonadherence to hypoglycemic medication, 
and that beliefs about the necessity and risk of antipsychotic 
medication use would be associated with nonadherence to 
antipsychotic medication. Because no previous studies have 
compared beliefs about hypoglycemic medication with 
beliefs about antipsychotic medication, these analyses were 
exploratory in nature.
Materials and methods
Study sample and setting
The 44 participants in this study had taken part in an earlier 
investigation comparing the processes and outcomes of care 
for type 2 diabetes between 201 individuals with a   coexisting 
serious mental illness and a comparison group without a 
psychiatric illness (n = 99). All participants had a medical 
chart diagnosis of type 2 diabetes, and were 18–65 years of 
age at time 1, English-speaking, and able to provide informed 
consent. Participants in the serious mental illness group had 
a medical chart diagnosis of schizophrenia, schizoaffec-
tive, bipolar, or major depressive disorder. A more detailed 
description of the recruitment strategies and assessment 
procedures is provided elsewhere.16
The 44 participants in the current study were further 
drawn from the 95/201 people (47%) with a serious mental 
illness who completed a 5-year follow-up assessment of 
the original study. Among these 95, 90 (95%) expressed an 
interest in participating in the current study on medication 
adherence and were screened for eligibility. To be included 
in the current study, participants had to be receiving one or 
more oral or injectable hypoglycemic medications prescribed 
routinely and at least one oral antipsychotic medication 
prescribed routinely. Among the 90 individuals considered 
for participation, 46 were not enrolled (39 did not meet eli-
gibility criteria, four could not be reached during the study 
time frame, two had died, and one was in a nursing home). 
The remaining 44 (49% of 90) were enrolled in the study. 
Compared with the individuals having serious mental illness 
who completed the 5-year follow-up assessment but who 
were not included in the current study, a larger proportion of 
participants in this study were diagnosed with schizophrenia 
rather than a mood disorder, and the participants in this study 
were younger than those who did not participate in this study. 
The groups did not differ on any other demographic, mental 
health-related, or diabetes-related characteristics. The institu-
tional review board of the University of Maryland School of 
Medicine approved the study, and all participants provided 
written informed consent to be interviewed and permitted a 
review of their medical records.
Data sources and measures
Between January 2006 and July 2007, all participants met 
with research staff for approximately 60–90 minutes to com-
plete an assessment of medication beliefs and   adherence. We 
used the Beliefs about Medication Questionnaire: Specific 
Version (BMQ-Specific),9 to characterize patients’ beliefs 
about the necessity of hypoglycemic and antipsychotic 
medications for controlling their illnesses and their concerns 
about the adverse consequences of taking the medications. 
Six of the 11 statements in the BMQ-Specific comprise 
a “  Concerns” subscale and five statements comprise a 
“  Necessity” subscale. One questionnaire was   administered 
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for all   hypoglycemic   medications, and another was 
administered for all   antipsychotic medications prescribed. 
  Respondents indicated their degree of agreement with the 
statements using a Likert scale ranging from 1 (strongly 
disagree) to 5 (strongly agree), with higher scores on the 
Necessity items indicating stronger beliefs about the neces-
sity of antipsychotic or hypoglycemic medications and higher 
scores on the Concerns items indicating greater concerns 
about adverse effects. The BMQ-Specific has satisfactory 
psychometric properties for use in individuals with severe 
mental disorders, demonstrating acceptable internal reli-
ability and test-retest reliability,17 as well as a relationship to 
related concepts of insight and illness perception17 and with 
psychotropic medication adherence in these patients.10,17
Participants were instructed to bring all currently pre-
scribed medications, in either bottles or as a list. Research 
staff noted the name, dosage strength, and frequency of 
administration for all medications prescribed on a routine 
(ie, not as needed) basis. We then determined the total 
number of medications prescribed, the number of hypogly-
cemic medications (oral or insulin) prescribed, the number 
of antipsychotic medications prescribed, and their directions 
for administration.
Nonadherence to hypoglycemic medications and to 
antipsychotic medications was ascertained using the Brief 
Medication Questionnaire.18 Research staff interviewed 
participants about their medication use, and then compared 
participants’ responses with the medications’ directions for 
use. The definition of adherence specified by the developers 
of the Brief Medication Questionnaire was employed in the 
current study. Participants who reported stopping the medi-
cine due to a late refill or other reason, missing any doses, 
or consuming greater than the prescribed amount during the 
past week were considered nonadherent to that particular 
medication.
Data analysis
To compare patients’ beliefs about antipsychotic medications 
versus hypoglycemic medications, we conducted a series of 
paired t-tests, comparing the BMQ-Specific Necessity sub-
scale score and Concerns subscale score for antipsychotic 
medications with their BMQ-Specific Necessity and Concerns 
subscale scores for hypoglycemic medications. Effect sizes 
are reported for these comparisons, correcting for dependence 
between means.19 Independent t-tests were used to compare 
beliefs about antipsychotic medications (BMQ-Specific 
Necessity and Concerns subscales) between antipsychotic-
nonadherent patients and   antipsychotic-adherent patients. 
The same statistical approach was used for hypoglycemic 
medications. McNemar’s test (binomial approximation) was 
used to assess whether the group’s self-reported nonadher-




The demographic, clinical, and diabetes-related charac-
teristics of the sample are shown in Table 1. A total of 
70% (31/44) of study participants were diagnosed with a 
  schizophrenia spectrum disorder and 30% (13/44) with a 
major mood disorder. Virtually all participants (43/44) had 
seen a mental health care provider in the past 6 months. Five 
percent (2/44) had been hospitalized for diabetes and 11% 
(5/44) had been hospitalized for psychiatric reasons in the 
6 months prior to assessment.
Beliefs about antipsychotic versus 
hypoglycemic medications
Individuals reported stronger beliefs about the necessity of 
their hypoglycemic medication versus their antipsychotic 
medication, as reflected in their higher scores on the BMQ 
Necessity subscale for hypoglycemic medications (mean 
4.08 ± 0.69) than for antipsychotic medications [mean 
3.80 ± 0.75; t (43) = −2.00, P = 0.05]. The effect size d 
of −0.31 indicates a small effect. There was a nonsignificant 
trend toward individuals having greater concerns about the 
overall risks of hypoglycemic medications versus antipsychot-
ics, as reflected in their higher scores on the BMQ Concerns 
Table 1 Demographic, clinical, and diabetes-related characteristics 
of sample (n = 44)
Demographic characteristics
Age (mean ± SD), years 51.1 (9.3)
gender, % female 55% (n = 24)
Race, % non-Caucasian 41% (n = 18)
% high school education or higher 71% (n = 31)
Diabetes-related characteristics
Duration of diabetes (mean ± SD), years 12.8 (6.4)
Total number of hypoglycemic medications  
prescribed (mean ± SD)
1.8 (0.8)




Total number of antipsychotic medications  
prescribed (mean ± SD)
1.2 (0.4)
Total number of medical conditions diagnosed  
(mean ± SD)
4.0 (2.4)
Total number of medications prescribed (mean ± SD) 10.3 (3.4)
Abbreviation: SD, standard deviation.
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subscale for hypoglycemic medications (mean 2.78 ± 0.79) 
than for antipsychotic medications [mean 2.61 ± 0.77, t 
(43) = −1.83, P = 0.07]. The effect size d of −0.27 indicates 
a small effect.
Relationship between medication  
beliefs and nonadherence
Neither beliefs about the necessity of antipsychotic medi-
cations nor concerns about their risks was associated with 
adherence to these agents. This is reflected in the similar 
scores on the BMQ Necessity subscale [mean 3.85 ± 0.67 
versus mean 3.69 ± 0.94; t (42) = 0.61, P = 0.55] and 
BMQ Concerns subscale [mean 2.61 ± 0.76 versus mean 
2.62 ± 0.84; t (42) = −0.03, P = 0.98] for those individuals 
adherent versus nonadherent to antipsychotic medications, 
respectively.
Similarly for hypoglycemic medications, neither beliefs 
about the necessity of medications nor concerns about their 
risks was associated with adherence to these medications. 
This is reflected in the similar scores on the BMQ   Necessity 
subscale [mean 4.22 ± 0.49 versus mean 3.70 ± 1.00; 
t (42) = 1.72, P = 0.11] and BMQ Concerns subscale [mean 
2.73 ± 0.75 versus mean 2.92 ± 0.91; t (42) = −0.67, P = 0.50] 
for those individuals adherent versus nonadherent to these 
medications, respectively.
Relationship between antipsychotic  
and hypoglycemic nonadherence
Individuals were no more likely to be nonadherent to their 
antipsychotic medications than to their hypoglycemic medi-
cations (P = 1.00). Eleven percent (5/44) of the patients were 
nonadherent with both their hypoglycemic and antipsychotic 
medications, 16% (7/44) were nonadherent to hypoglycemic 
medication only, 18% (8/44) were nonadherent to antipsy-
chotic medication only, and 55% (24/44) were adherent to 
both medication types.
Discussion
This study is the first to find evidence that individuals with 
coexisting serious mental illness and a chronic medical condi-
tion, ie, type 2 diabetes, felt the medication for their chronic 
medical condition to be more necessary to their health than 
antipsychotic medication. This finding corresponds well 
with research demonstrating relatively good adherence to 
diabetes medication in individuals with serious mental illness 
diagnoses.14,15 When one considers the severe, sometimes 
irreversible, consequences of poorly managed diabetes, 
including blindness, cardiovascular disease, or the loss of 
a limb, such strong beliefs about the necessity of managing 
this illness are understandable. Furthermore, the immediate 
consequences of hypoglycemic medication nonadherence, 
such as polyuria and blurred vision, may be more readily 
apparent to the patient than the immediate consequences of 
nonadherence to antipsychotic medication, of which there 
may be none. The consequences of poor diabetes manag-
ment may also be somewhat more concrete and less subject 
to issues of insight and subjective impression than are the 
symptoms of mental illness.
The diagnostic composition of the sample in this study 
could have affected the results. Thirty percent of the indi-
viduals in the study were diagnosed with affective disorders, 
including treatment-refractory major depressive disorder 
and bipolar disorder. Although some antipsychotics are 
approved by the US Food and Drug Administration for 
treatment of these disorders, antipsychotics are possibly 
more often prescribed in conjunction with a mood stabi-
lizer or an antidepressant, and may thus be perceived as 
less essential to long-term health by individuals with mood 
disorders. The difference in beliefs about the importance of 
hypoglycemic versus antipsychotic medications for future 
health could have been, in part, due to beliefs about the 
relative unimportance of antipsychotic medications held 
by those with a mood   disorder. Future research involving a 
larger sample size should explore differences in medication 
beliefs among individuals carrying different serious mental 
illness diagnoses.
Contrary to the study hypotheses and in contrast with 
previous research,6–8,10,11 there was no significant relation-
ship between medication beliefs and nonadherence for either 
type of medication. It is possible that our small sample could 
have precluded our ability to detect an association between 
medication beliefs and adherence. That said, it is worth noting 
that medication attitudes are only one of many factors affect-
ing adherence. Although patient adherence is also affected 
by other factors, including medication costs, side effects, 
and cognitive impairments, in addition to attitudes held by 
the patient, evaluating the effects of these other factors on 
adherence was beyond the scope of this study.
Patients in this study were equally as likely to be adherent 
to their antipsychotic medication as to their hypoglycemic 
medication. Although past findings are mixed,20 the current 
results correspond with previous research suggesting no 
differences in adherence between psychotropic and somatic 
medications.21,22 Our findings may be related to the fact that 
over half of the patients in this study reported adherence to 
both medication types. This high rate of adherence may be 
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a reflection of our use of self-report adherence data, which 
may have led to inflated estimates of medication adherence.23 
However, a recent meta-analysis suggests that adherence 
estimates based on self-report do not appear to be grossly 
inflated.24 Furthermore, the study employed a very conserva-
tive definition of adherence, which could plausibly have led 
to fewer individuals categorized as adherent than found in 
studies using a more liberal definition.
This study sample was composed of those individuals 
willing to participate in follow-up from an earlier study 
of diabetes self-management and outcomes, and it is pos-
sible that individuals adherent to their medication regimens 
would more readily agree to the follow-up session than those 
who were nonadherent. This potential selection bias could 
  diminish the generalizability of the results, because this 
subsample of patients may demonstrate greater adherence 
than the population of interest.
Conclusion
Limitations notwithstanding, this study presents noteworthy 
information regarding beliefs about medication not previously 
reported in the literature. The results of this study indicate that 
individuals with coexisting serious mental illness and type 2 
diabetes are more convinced of the importance of managing 
their chronic medical condition than their mental illness.
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